cell-therapy

Brain-Referenced In vivo-to-in vitro Developmental Guidance and Evaluation.

single cell RNA-seq analysis of human gastric insulin-secreting (GINS) organoids

Interactive dashboard tracking CAR-T, CAR-NK, CAAR-T, and CAR-γδ T clinical trials across heme- and solid-onc from ClinicalTrials.gov v2. Sister app to Rheumatology-CAR-T-Trials-Monitor.

Aspect Biosystems is a Vancouver, British Columbia biotechnology company developing Bioprinted Tissue Therapeutics — implantable, allogeneic living tissues designed to replace, repair, or supplement biological function in the body.

CREATE Medicines is a Cambridge, Massachusetts biopharmaceutical company developing in vivo CAR (chimeric antigen receptor) cell therapies using mRNA lipid-nanoparticle (mRNA-LNP) delivery.

Cell therapy manufacturing analytics portfolio — CPV dashboards, OOT investigation, and golden batch monitoring

Abata Therapeutics was a biotechnology company developing engineered regulatory T cell (Treg) therapies aimed at restoring immune tolerance in tissue-specific autoimmune and inflammatory diseases, with lead programs directed at progressive multiple sclerosis and type 1 diabetes.

3T Biosciences is a clinical-stage immunotherapy company based in South San Francisco, developing next-generation T-cell receptor (TCR) therapeutics for solid tumors and other immune-mediated diseases. Founded in 2017 on research from K.

SQZ Biotech is a company surfaced as a portfolio company of gv and added to the API Evangelist network as a stub for enrichment. Sector: life-sciences. This profile is a lead awaiting the enrichment pipeline.

Novoprotein (Suzhou Novoprotein Scientific / 苏州近岸蛋白质科技股份有限公司) is a Chinese biotechnology company specializing in recombinant protein preparation and related life-science reagents and contract research services.

Synthekine is a clinical-stage biotechnology company discovering, developing, and commercializing the next generation of selective cytokine therapeutics. The company believes cytokine therapeutics engineered to be selective can fundamentally change the treatment paradigm for cancer and inflammatory disease.

Cell Design Labs, Inc. was a biotherapeutics company based at 5858 Horton Street, Emeryville, California, that engineered immune cells into "smart, living therapies" for cancer and other diseases.

XellSmart Biomedical (士泽生物医药) is a clinical-stage biotechnology company based in Suzhou and Shanghai, China, founded in 2021 by Dr. Xiang Li. The company develops clinical-grade, allogeneic, off-the-shelf iPSC-derived cell therapies for central nervous system diseases, with NMPA- and U.S.

TScan Therapeutics (Nasdaq: TCRX) is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts developing T-cell receptor engineered T-cell (TCR-T) therapies for the treatment of patients with cancer.

Sana Biotechnology is a clinical-stage biotechnology company (NASDAQ: SANA) focused on engineering cells as medicines. Its platforms repair or control genes inside cells and replace missing or damaged cells to address the underlying causes of disease, with drug candidates spanning type 1 diabetes, B-cell cancers, and B-cell-mediated autoimmune…

ImmuneBridge is a San Francisco biotech company building a first-in-class integrated screening and manufacturing platform for allogeneic cell therapies. The company screens and expands stem cells from multiple sources (umbilical cord blood, mobilized blood, bone marrow), uses high-throughput automated assays with machine-learning models to predict…

Cure Genetics (克睿基因) is a clinical-stage biotechnology company founded in 2016 and based in Suzhou, Jiangsu, China, developing cell and gene therapies for solid tumors and genetic diseases.

Sonoma Biotherapeutics is a clinical-stage biopharmaceutical company developing engineered regulatory T cell (Treg) therapies to restore immune balance in autoimmune and inflammatory diseases.

Umoja Biopharma is a Seattle-based clinical-stage immuno-oncology company developing in vivo CAR T cell therapies for cancer. Its VivoVec lentiviral platform generates CAR T cells directly in a patient's body, removing the ex vivo manufacturing step of traditional cell therapy, and the company operates its own manufacturing facility in Louisville…

Oricell Therapeutics (原启生物) is a Shanghai-based clinical-stage biopharmaceutical company developing cell-based immunotherapies for cancer, including GPC3-targeted CAR-T (Ori-C101) for advanced liver cancer and GPRC5D-targeted CAR-T (OriCAR-017) for relapsed/refractory multiple myeloma.